{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:29:19Z","timestamp":1788262159555,"version":"build-2803163510"},"reference-count":68,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: The introduction of tyrosine kinase inhibitors has transformed chronic myeloid leukemia into a chronic condition with near-normal life expectancy, shifting clinical priorities toward long-term tolerability, symptom burden, and health-related quality of life. This review aims to synthesize current evidence on patient-reported outcomes and quality of life in chronic myeloid leukemia, with particular focus on fatigue, differences across therapies, associations with molecular response and treatment-free remission, and health utility outcomes. Methods: A narrative review of published clinical trials, observational studies, and patient-reported outcome research in chronic myeloid leukemia during the tyrosine kinase inhibitor era was conducted. Evidence from generic, cancer-specific, and disease-specific quality-of-life instruments was examined, together with studies evaluating dose reduction, treatment discontinuation, and survivorship outcomes. Results: Across studies, patients with chronic myeloid leukemia experience persistent impairments in quality of life compared with the general population despite effective disease control. Fatigue consistently emerges as the dominant symptom associated with functional limitation and reduced well-being. Comparative analyses across tyrosine kinase inhibitors demonstrate generally modest and inconsistent differences in global quality of life. Deeper molecular responses, dose reduction, and treatment-free remission are commonly associated with stabilization or improvement in patient-reported outcomes, although symptoms may persist in a subset of patients. Methodological limitations include heterogeneity of instruments, predominance of cross-sectional designs, and lack of established minimal important differences for disease-specific measures. Conclusions: In the modern treatment era, chronic myeloid leukemia is characterized by excellent survival but an ongoing quality-of-life burden, largely driven by fatigue. Future research should prioritize longitudinal patient-reported outcome collection, methodological standardization, and development of clinically meaningful thresholds to better align disease control with patient-centered outcomes.<\/jats:p>","DOI":"10.3390\/cancers18071133","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T10:09:21Z","timestamp":1775038161000},"page":"1133","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Current Overview of Quality-of-Life Research in Chronic Myeloid Leukemia (CML)"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1888-5567","authenticated-orcid":false,"given":"Stefan","family":"Deneberg","sequence":"first","affiliation":[{"name":"Karolinska Institutet, Institutionen f\u00f6r Medicin Huddinge, ME Hematologi, Karolinska University Hospital, 141 57 Huddinge, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e35953","DOI":"10.1002\/cncr.35953","article-title":"Management of chronic myeloid leukemia in 2025","volume":"131","author":"Kantarjian","year":"2025","journal-title":"Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population","volume":"34","author":"Bower","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","article-title":"Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: Analysis of patient data from six prospective clinical trials","volume":"2","author":"Sasaki","year":"2015","journal-title":"Lancet Haematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1182\/blood.2024026310","article-title":"The Evolution of Treatment-Free Remission","volume":"145","author":"Hughes","year":"2025","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41375-025-02664-w","article-title":"2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"39","author":"Apperley","year":"2025","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3324\/haematol.2013.094045","article-title":"Moving towards patient-centered decision-making in chronic myeloid leukemia: Assessment of quality of life and symptom burden","volume":"99","author":"Baccarani","year":"2014","journal-title":"Haematologica"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s11899-021-00656-y","article-title":"Health-Related Quality of Life of Patients with Chronic Myeloid Leukemia as Measured by Patient-Reported Outcomes: Current State and Future Directions","volume":"16","author":"Schoenbeck","year":"2021","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med. Care"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","article-title":"Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population","volume":"118","author":"Efficace","year":"2011","journal-title":"Blood"},{"key":"ref_10","first-page":"1097","article-title":"Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: A controlled comparison","volume":"21","author":"Phillips","year":"2013","journal-title":"Support. Care Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/leu.2013.51","article-title":"Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib","volume":"27","author":"Efficace","year":"2013","journal-title":"Leukemia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00277-015-2541-6","article-title":"The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia","volume":"95","author":"Efficace","year":"2016","journal-title":"Ann. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2050312116671725","DOI":"10.1177\/2050312116671725","article-title":"SF-36 total score as a single measure of health-related quality of life: Scoping review","volume":"4","author":"Lins","year":"2016","journal-title":"SAGE Open Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual. Life Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1007\/s11136-021-02794-5","article-title":"Health state utility and quality of life measures in patients with chronic myeloid leukemia in France","volume":"30","author":"Foulon","year":"2021","journal-title":"Qual. Life Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jval.2012.08.2210","article-title":"Measuring health-related quality of life in leukemia: The Functional Assessment of Cancer Therapy--Leukemia (FACT-Leu) questionnaire","volume":"15","author":"Cella","year":"2012","journal-title":"Value Health"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2018.11.024","article-title":"General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States","volume":"107","author":"Nolte","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s11136-013-0523-5","article-title":"International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: The EORTC QLQ-CML24","volume":"23","author":"Efficace","year":"2014","journal-title":"Qual. Life Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1080\/10428194.2020.1838509","article-title":"Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia","volume":"62","author":"Efficace","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1182\/blood-2013-01-477687","article-title":"Measuring the symptom burden associated with the treatment of chronic myeloid leukemia","volume":"122","author":"Williams","year":"2013","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jmpt.2003.11.003","article-title":"Assessing the clinical significance of change scores recorded on subjective outcome measures","volume":"27","author":"Hurst","year":"2004","journal-title":"J. Manip. Physiol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"PharmacoEconomics"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/ejh.14328","article-title":"Loss in Overall and Quality-Adjusted Life Expectancy for Patients With Chronic-Phase Chronic Myeloid Leukemia","volume":"114","author":"Chen","year":"2025","journal-title":"Eur. J. Haematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1200\/JCO.2004.02.018","article-title":"Quality of life in patients with colorectal cancer 1 year after diagnosis compared with the general population: A population-based study","volume":"22","author":"Arndt","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.ejca.2003.12.007","article-title":"Age-specific detriments to quality of life among breast cancer patients one year after diagnosis","volume":"40","author":"Arndt","year":"2004","journal-title":"Eur. J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/S0277-9536(99)00045-3","article-title":"Integrating response shift into health-related quality of life research: A theoretical model","volume":"48","author":"Sprangers","year":"1999","journal-title":"Soc. Sci. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.3324\/haematol.2020.247767","article-title":"Fatigue in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy: Predictors and the relationship with physical activity","volume":"106","author":"Janssen","year":"2021","journal-title":"Haematologica"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1182\/blood.V118.21.3138.3138","article-title":"Identifying High Symptom Burden in Patients with Chronic Myeloid Leukemia on Tyrosine Kinase Inhibitor Therapy","volume":"118","author":"Williams","year":"2011","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1182\/blood.V118.21.3771.3771","article-title":"Memory Impairment in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Treated with Dasatinib Tyrosine Kinase Inhibitor (TKI) Therapy","volume":"118","author":"Pemmaraju","year":"2011","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1182\/blood.V126.23.5147.5147","article-title":"Outcomes of Second-Line Treatment By Dasatinib in Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia Patients with and without Comorbidities","volume":"126","author":"Ionova","year":"2015","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.htct.2019.01.003","article-title":"A case of neurocognitive deficit strongly related to dasatinib therapy","volume":"42","author":"Chamoun","year":"2020","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Jones, A., Bonomi, S., Stockerl-Goldstein, K.E., and Bateman, R.J. (2025). Neuropsychiatric Symptoms Mimicking Dementia in a Patient Treated With Imatinib. Ann. Clin. Transl. Neurol.","DOI":"10.1002\/acn3.70296"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/arclin\/acs141","article-title":"Predictors of neuropsychological change in patients with chronic myelogenous leukemia and myelodysplastic syndrome","volume":"28","author":"Meadows","year":"2013","journal-title":"Arch. Clin. Neuropsychol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1080\/10428194.2022.2070912","article-title":"Lower tumor burden is associated with better cognitive function in patients with chronic phase chronic myeloid leukemia","volume":"63","author":"Li","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Yu, L., Wang, H., Milijkovic, D., Huang, X., and Jiang, Q. (2018). Achieving optimal response at 12 months is associated with a better health-related quality of life in patients with chronic myeloid leukemia: A prospective, longitudinal, single center study. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4699-5"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00277-020-04018-1","article-title":"Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia","volume":"99","author":"Bushmakin","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5457","DOI":"10.1002\/cam4.1808","article-title":"A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors","volume":"7","author":"Lin","year":"2018","journal-title":"Cancer Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1182\/blood.2024026311","article-title":"Long-term outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"145","author":"Guilhot","year":"2025","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrclinonc.2014.127","article-title":"Cancer-related fatigue--mechanisms, risk factors, and treatments","volume":"11","author":"Bower","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nrn2297","article-title":"From inflammation to sickness and depression: When the immune system subjugates the brain","volume":"9","author":"Dantzer","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41375-019-0563-0","article-title":"Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy","volume":"34","author":"Efficace","year":"2020","journal-title":"Leukemia"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1007\/s00432-019-02894-3","article-title":"Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia","volume":"145","author":"Cortes","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1182\/blood.V120.21.3166.3166","article-title":"Assessment of Patient Reported Outcomes (PROs) From the Enestnd Trial with Minimum Follow-up of 36 Cycles","volume":"120","author":"Beaumont","year":"2012","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1038\/s41375-023-01888-y","article-title":"Health-related quality of life of patients with resistant\/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial","volume":"37","author":"Boquimpani","year":"2023","journal-title":"Leukemia"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1182\/blood-2025-1997","article-title":"Asciminib (ASC) demonstrates continued improvement in patient-reported outcomes (PROs) vs investigator-selected tyrosine kinase inhibitors (IS-TKIs) in newly diagnosed chronic myeloid leukemia (CML): ASC4FIRST week 96 analysis","volume":"146","author":"Cortes","year":"2025","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1200\/JCO.2003.12.154","article-title":"Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: Results from the IRIS Study","volume":"21","author":"Hahn","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1002\/cncr.31323","article-title":"Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib","volume":"124","author":"Efficace","year":"2018","journal-title":"Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1182\/blood.V118.21.1025.1025","article-title":"Does Baseline Health-Related Quality of Life or Symptom Burden Predict Clinical Outcomes in Patients with Newly Diagnosed CML-CP Treated with Nilotinib or Imatinib?","volume":"118","author":"Beaumont","year":"2011","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1182\/blood.V124.21.1321.1321","article-title":"Prospective Analysis of the Quality of Life of Chronic Phase CML Patients on Second Generation Tyrosine Kinase Inhibitors after Imatinib Failure. an Observational Study","volume":"124","author":"Nicolini","year":"2014","journal-title":"Blood"},{"key":"ref_52","first-page":"318","article-title":"Molecular Responses after Switching from a Standard-Dose Twice-Daily Nilotinib Regimen to a Reduced-Dose Once-Daily Schedule in Patients with Chronic Myeloid Leukemia: A Real Life Observational Study (NILO-RED)","volume":"130","author":"Rea","year":"2017","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/bjh.17654","article-title":"Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients","volume":"194","author":"Rousselot","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1182\/blood.2021012082","article-title":"Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: A randomized, open-label phase 2 clinical trial","volume":"138","author":"Cortes","year":"2021","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e375","DOI":"10.1016\/S2352-3026(19)30094-8","article-title":"De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): A non-randomised, phase 2 trial","volume":"6","author":"Clark","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_56","first-page":"918","article-title":"Interim analysis of a multicenter study on patient-guided dose reduction of tyrosine kinase inhibitors in chronic myeloid leukemia: The RODEO study","volume":"111","author":"Lokhorst","year":"2026","journal-title":"Haematologica"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e2347950","DOI":"10.1001\/jamanetworkopen.2023.47950","article-title":"Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia","volume":"6","author":"Winn","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): A prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1038\/s41375-024-02341-4","article-title":"Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: Results from the EURO-SKI Trial","volume":"38","author":"Efficace","year":"2024","journal-title":"Leukemia"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jval.2024.12.005","article-title":"The Cost-Effectiveness of Frontline Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia: In Pursuit of Treatment-Free Remission and Dose Reduction","volume":"28","author":"Metsemakers","year":"2025","journal-title":"Value Health"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1200\/JCO.2014.55.6910","article-title":"Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: A tyrosine kinase inhibitor withdrawal syndrome?","volume":"32","author":"Richter","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1038\/s41375-020-0867-0","article-title":"Treatment-free remission in chronic myeloid leukemia: The patient perspective and areas of unmet needs","volume":"34","author":"Sharf","year":"2020","journal-title":"Leukemia"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.2147\/PPA.S369326","article-title":"Psychological Factors Affecting the Willingness to Accept a Possible Tyrosine Kinase Inhibitor (TKI) Discontinuation in Chronic Myeloid Leukaemia (CML) Patients","volume":"16","author":"Cutica","year":"2022","journal-title":"Patient Prefer. Adherence"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/jnci\/djab184","article-title":"Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors","volume":"114","author":"Schoenbeck","year":"2022","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"43","DOI":"10.6004\/jnccn.2024.0007","article-title":"Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Shah","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s00277-012-1458-6","article-title":"Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group","volume":"91","author":"Efficace","year":"2012","journal-title":"Ann. Hematol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/cncr.32521","article-title":"Internet-assisted cognitive behavioral intervention for targeted therapy-related fatigue in chronic myeloid leukemia: Results from a pilot randomized trial","volume":"126","author":"Jim","year":"2020","journal-title":"Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e010938","DOI":"10.1136\/bmjopen-2015-010938","article-title":"Design, implementation and reporting strategies to reduce the instance and impact of missing patient-reported outcome (PRO) data: A systematic review","volume":"6","author":"Palmer","year":"2016","journal-title":"BMJ Open"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/7\/1133\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T10:21:44Z","timestamp":1775038904000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/7\/1133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":68,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["cancers18071133"],"URL":"https:\/\/doi.org\/10.3390\/cancers18071133","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]}}}